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Background: Although results of case series support the use of spinal cord stimulation in failed back surgery
syndrome patients with predominant low back pain, no confirmatory randomized controlled trial has been
undertaken in this patient group to date. PROMISE is a multicenter, prospective, randomized, open-label,
parallel-group study designed to compare the clinical effectiveness of spinal cord stimulation plus optimal
medical management with optimal medical management alone in patients with failed back surgery syndrome
and predominant low back pain.
Method/Design: Patients will be recruited in approximately 30 centers across Canada, Europe, and the United
States. Eligible patients with low back pain exceeding leg pain and an average Numeric Pain Rating Scale score ≥5
for low back pain will be randomized 1:1 to spinal cord stimulation plus optimal medical management or to
optimal medical management alone. The investigators will tailor individual optimal medical management treatment
plans to their patients. Excluded from study treatments are intrathecal drug delivery, peripheral nerve stimulation,
back surgery related to the original back pain complaint, and experimental therapies. Patients randomized to the
spinal cord stimulation group will undergo trial stimulation, and if they achieve adequate low back pain relief a
neurostimulation system using the Specify® 5-6-5 multi-column lead (Medtronic Inc., Minneapolis, MN, USA) will be
implanted to capture low back pain preferentially in these patients. Outcome assessment will occur at baseline
(pre-randomization) and at 1, 3, 6, 9, 12, 18, and 24 months post randomization. After the 6-month visit, patients
can change treatment to that received by the other randomized group. The primary outcome is the proportion of
patients with ≥50% reduction in low back pain at the 6-month visit. Additional outcomes include changes in low
back and leg pain, functional disability, health-related quality of life, return to work, healthcare utilization including
medication usage, and patient satisfaction. Data on adverse events will be collected. The primary analysis will follow
the intention-to-treat principle. Healthcare use data will be used to assess costs and long-term cost-effectiveness.
Discussion: Recruitment began in January 2013 and will continue until 2016.
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Following lumbosacral spine surgery, between 5 and
50% of patients suffer from chronic back and/or leg pain,
commonly known as failed back surgery syndrome
(FBSS) [1,2] and characterized by disabling neuropathic
radicular leg pain with or without low back pain, which
might have mixed neuropathic and nociceptive pain
components [3]. FBSS can be disabling and can have a
negative impact on a patient’s health-related quality of
life, well-being, and productivity [4,5].
Treatment of FBSS pain by further operations or med-
ical management is often unsuccessful and places a
heavy economic financial burden on healthcare systems
[2,3]. In contrast, randomized controlled trials (RCTs)
have shown spinal cord stimulation (SCS) to be a clinic-
ally effective and cost-effective adjunct to medical man-
agement [6-8] or alternative to a further operation [9,10]
in patients with FBSS characterized by leg pain exceed-
ing or equaling axial low back pain.
The effective targeting of the back pain component of
FBSS remains a challenge [11-13]. Ongoing development
of SCS leads and electrode arrays has included creation
of an insulated paddle with a multicolumn design and a
greater number of contacts than was formerly available:
all of these features improve low back coverage [14-16].
A pilot study has demonstrated the efficacy of a multi-
column SCS lead configuration for the treatment of the
axial back pain component of FBSS [17]. RCT evidence
is needed to confirm the efficacy of the use of multicol-
umn SCS in patients with FBSS characterized by pre-
dominant back pain.
Aims and objectives
The PROMISE study is a RCT comparing the clinical ef-
fectiveness of SCS using the Specify® 5-6-5 surgical lead
(Medtronic, Inc., Minneapolis, MN, USA) plus optimal
medical management (OMM) versus OMM alone in pa-
tients suffering from predominant low back pain due to
FBSS. After the 6-month visit, patients can change treat-
ment to that received by the other randomized group.
All patients will be followed for 24 months post
randomization.
The primary objective is to determine the difference in
the proportion of patients receiving SCS plus OMM ver-
sus the proportion receiving OMM alone who have
≥50% reduction in back pain intensity, as measured by
the Numeric Pain Rating Scale (NPRS), from baseline to
6 months. Secondary objectives are to compare changes
in the following outcomes from baseline to 6 months be-
tween the two groups: low back pain intensity, as mea-
sured by the NPRS [18]; leg pain intensity, as measured
by the NPRS [18]; functional disability, as measured by
the Oswestry Disability Index [19]; and quality of life, as
measured by the Short-Form Health Survey, version 2physical component summary score [20]. Additional ob-
jectives include the comparison of other patient-related
outcomes and healthcare utilization including medication
usage (see below) at 6 months, to assess within-patient
changes (that is, compared with pre-randomization) in
outcomes from 6 to 24 months post randomization, to
characterize all SCS-related and non-SCS-related adverse
events, and to assess the costs and cost-effectiveness of
SCS plus OMM versus OMM alone.
Methods/Design
This protocol is reported in accord with the SPIRIT
2013 guidance for protocols of clinical trials [21].
Design and setting
This multicenter study has an open-label, randomized,
parallel-group design. Patients will be randomized 1:1 to
SCS using the Specify® 5-6-5 surgical lead (Medtronic,
Inc.) plus OMM (SCS group) or to OMM alone (OMM
group) and followed for 6 months (Period I, randomized
comparative phase). After completion of the 6-month
(Period I) outcome assessment, patients will be system-
atically reminded (through electronic tablets used for
questionnaire completion) that they have completed the
randomized period of the study and can change treat-
ment to that received by the other randomized group.
Reasons for treatment switching will be recorded. Pa-
tients will be followed to 24 months post randomization
(Period II, long-term observational follow-up phase).
The trial will be conducted at approximately 30 inves-
tigative sites globally, with approximately 15 to 20 sites
in the USA and 10 to 15 sites in Europe and Canada.
Additional locations may be added during the course of
the study. No single center can exceed 10% of all ran-
domized patients. The study design is summarized in
Figure 1.
Selection of patients
The study population comprises patients suffering from
chronic low back (predominant) and leg pain due to
FBSS. A patient must meet all of the inclusion criteria
and none of the exclusion criteria to be eligible for the
study.
Inclusion criteria
The subject is a candidate for SCS with the multicolumn
Specify® 5-6-5 surgical lead (see Additional file 1); has
FBSS and does not require further surgery (for the pur-
poses of this study, FBSS is defined as persistent or re-
current low back and leg pain of at least 6 months
duration, following at least one decompression and/or
fusion procedure); presents average low back pain ≥5
and that is greater than leg pain as assessed by the base-
line NPRS; and has persistent low back and leg pain
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Figure 1 PROMISE trial patient flow. *Therapy change may occur at any time post 6-month visit. OMM, optimal medical management; SCS,
spinal cord stimulation.
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gical, physical, or psychological therapies) that have been
tried and did not prove satisfactory, are unsuitable, or are
contraindicated for the subject.
Exclusion criteria
The subject is being treated or has been treated with
SCS, subcutaneous or peripheral nerve stimulation, being
treated with an intrathecal drug delivery system or re-
quires back surgery at the location related to his/her ori-
ginal back pain complaint or experimental therapies; had
most recent back surgery less than 6 months ago; has low
back pain only (no leg pain) as assessed by the baseline
NPRS; is suspected by the investigator of substance abuse
that might confound the study results; has unresolvedmajor issues of secondary gain, as determined by the in-
vestigator; exhibits major psychiatric morbidity, untreated
or refractory to treatment as determined by the investiga-
tor; has consistent severe pain (that is, 10 out of 10) with-
out fluctuation, which might confound the results of this
study; has radiographic evidence of instability requiring fu-
sion; has pain relieved completely by recumbency (mech-
anical pain); has a serious neurologic deficit; has a history
of coagulation disorder, lupus erythematosus, diabetic
neuropathy, rheumatoid arthritis, or ankylosing spondyl-
itis; has calcific arachnoiditis; has severe thoracic stenosis;
has life expectancy < 24 months beyond study enrolment;
is <18 years of age; is pregnant or planning to become
pregnant during the course of the study; is enrolled in or
plans to enroll in any study that might confound the
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equipment, based on the opinion of the principal or sub-
investigator; is unwilling to be treated with SCS, attend
visits as scheduled, and/or comply with study require-
ments; is unable to undergo study assessments or complete
questionnaires independently (for example, is illiterate);
and is a member of a vulnerable population.
A screening log will be kept at each site to identify po-
tential subjects. All FBSS patients identified through
standard clinical practice at the site (for example, call
log, chart review, scheduled visits, and referrals) will be
listed on the screening log. Potentially eligible subjects
will be provided with detailed information about the
study including a description of SCS and of OMM.
A patient is considered enrolled in the study upon com-
pletion of the informed consent process. Enrolled subjects
will be taught how to complete a pain diary between the
enrolment visit and the randomization visit. The subject
will record his/her low back and leg pain scores during a
7-day pain diary period prior to randomization. Subjects
will not be told what confirmatory pain scores are re-
quired for study inclusion. The inclusion criteria of aver-
age NPRS score to assess low back and leg pain will be
evaluated after the subject completes the pain diary. Can-
didacy for SCS with the Specify® 5-6-5 implant will also be
confirmed based on appropriate imaging according to
usual practice. In addition, where a psychological evalu-
ation (or other evaluation) is standard of care and/or
required, the evaluation must take place prior to ran-
domization. The principal investigator will document
whether the patient has received the required evaluation
and the results of that evaluation. FBSS diagnosis will also
be confirmed based on appropriate imaging according to
usual practice.
The principal investigator or his/her designee will review
the diary to confirm that the pain intensity scores and pain
location meet the inclusion/exclusion criteria (see above).
In addition, the principal investigator will document that
the patient is a candidate for implantation of a Specify®
5-6-5 SCS system. Upon confirmation of eligibility, OMM
treatment planning and completion of the questionnaires,
subjects will be randomized to one of the two treatment
groups. Subjects who do not complete or meet prelimin-
ary eligibility requirements will not be randomized and
will be exited from the study.
Interventions
Pain treatment will be evaluated, and medical manage-
ment of patient’s pain will be optimized in both arms.
As part of the confirmation of eligibility (prior to
randomization), the investigator and subject will deter-
mine an individual OMM treatment plan, which should
include non-investigational pharmacologic agents (for
example, tricyclic antidepressants, opioid analgesics ortramadol, antiepileptics, or lidocaine) and/or interven-
tional therapies (for example, therapeutic injections, radio-
frequency, acupuncture, functional restoration, physical
therapy, and psychological interventions, such as cognitive
behavioral therapy) as appropriate. The following treat-
ments are excluded from OMM: intrathecal drug delivery,
peripheral nerve stimulation (not an approved indication
in the United States), back surgery at the location related
to the patient’s original back pain complaint, and experi-
mental therapies. Data regarding pain treatments imple-
mented during the study will be collected to reveal how
medical management was optimized. After randomization,
as well as at all scheduled follow-up visits, the subject and
physician will further discuss OMM to determine the best
course of continued action.
In addition to OMM, patients randomized to the SCS
arm will undergo an SCS screening test (3-day mini-
mum). The screening test may be conducted with the
Specify® 5-6-5 surgical lead or with a percutaneous lead(s).
If successful, a SCS system will be implanted. A
screening test will be determined to be successful if the
subject finds the feeling of paresthesia acceptable and has
adequate low back pain relief with usual activity and
appropriate analgesia as assessed by the physician. Physi-
cians can consider a conducting second screening test
with the Specify® 5-6-5 lead if a screening test with a
percutaneous lead led to inadequate paresthesia coverage
of low back pain and/or painful extraneous stimulation
(for example, chest wall pain, pressure or sharp mid-
back pain). The final system implanted will consist of a
Medtronic pulse generator (rechargeable or primary cell)
and a Specify® 5-6-5 surgical lead. Subjects should re-
ceive their permanent implant within 60 calendar days
from randomization. They will be programmed to their
optimal programming parameters and will be able to ad-
just their stimulation with the patient programmer,
within the settings programmed in the clinic. Subjects
will be provided with a patient programmer manual and
will be instructed on the proper use and handling of the
patient programmer. Subjects who fail the screening test
(and do not proceed to implant) will be followed in the
study according to the principles of intention-to-treat
analysis.
Assessments
Outcome measures selected for this trial are based on a
review of the previous RCTs of SCS and a consideration
of IMMPACT recommendations [18].
The day of randomization is day 0 for the study periods.
Subjects will be assessed prior to randomization (baseline)
and at 1-month, 3-month, 6-month, 9-month, 12-month,
18-month and 24-month follow-up visits. Visit windows
for Period I and Period II will remain constant based on
the original date from the randomization visit, regardless
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be performed by appropriately trained and delegated study
staff according to the usual practices of the site. Electronic
case report forms will be used for this study with patients
completing the study questionnaires confidentially on
electronic tablets, and these data will be uploaded to a
web-based server. Table 1 provides a summary of the data
collection process and timing.
Primary outcome
The primary outcome is the proportion of subjects with
≥50% reduction in low back pain intensity measured
using the NPRS at 6 months [18]. Pain relief will be
assessed as a reduction of the 11-point NPRS. Patients
will record their low back and leg pain using a (paper)
pain diary two times per day, once in the morning and
once in the evening, for a 7-day period within 2 weeks
prior to the randomization visit and subsequent sched-
uled study visits. For the initial baseline pain diary,
patients are required to complete at least 5 of 7 days in
their entirety, or they will not proceed to randomization.
The proportion of subjects in each group with ≥50% re-
duction in average low back pain score at the end of
Period I compared with baseline will be calculated.
Secondary outcomes
Secondary outcomes are: Back and leg NPRS score [18];
Oswestry Disability Index version 2 [19]; and Physical
Component Summary score on the Short-Form 36 [20].
Other outcomes include: Mental Component Summary
score on Short-Form 36 [20]; EuroQoL 5D-5 L (EQ-5D-
5 L) [22]; Pittsburgh Sleep Quality Index [23]; healthcare
use related to the pain condition and to its treatment (for
example, managing adverse events, interventions, investi-
gations, drugs, length and number of inpatient hospitaliza-
tions, and number of emergency room, office, and other
healthcare-related visits) [24]; employment status (‘What
is your current employment status?’, ‘If out of work: what
is the main reason you are out of work?’); patient satisfac-
tion (‘Would you recommend this therapy to patients suf-
fering from pain similar to yours?’, ‘Overall how satisfied
or unsatisfied are you with this therapy?’); Patient Global
Impression of Change version 2 [25]; programming pa-
rameters and paresthesia coverage; and adverse events
(adverse events and device deficiencies documentation will
include date of adverse event or device deficiency, diagno-
sis and description of the event, assessment of seriousness
of the event, treatment of the event, outcome or resolution
and date of the event, and relationship of the event to the
device or to OMM – in addition to the standard question-
naire data collection schedule, the EQ-5D-5 L will be col-
lected, when possible, whenever a device-related adverse
event occurs that might require a surgical intervention or
hospitalization).Process measures
At the screening and baseline visits, the following add-
itional information will be collected: subject demograph-
ics (for example, age, gender) and a neuropathic pain
assessment by clinician-administered diagnostic ques-
tionnaire (Douleur Neuropathique en 4 questions) to
discriminate neuropathic pain components of low back
pain [26]. Subjects who proceed to device implantation
will have the following information collected: pain/
paresthesia map, parameter settings, electrode location,
and device implant information (that is, model, serial
number). Patients receiving SCS therapy will have a de-
vice interrogation at each visit, and at only the 6-month
visit data will be gathered on the parameters at which
SCS paresthesia is perceived, is comfortable, and be-
comes uncomfortable. Unscheduled patient visits could
occur between scheduled study follow-up visits due to
patient discontinuation from the study or device repro-
gramming and management of any complications.Sample size and power calculations
Based on the results of the PROCESS study [8], with the
assumption that OMM will provide slightly better low back
pain relief and a conservative estimate using intention-to-
treat analysis, the sample size calculation assumed a 20%
between-group difference in the responder rate, which is
defined as patients achieving ≥50% low back pain relief,
with a 40% response rate for the SCS group and 20% for
OMM group. The sample size was calculated using EAST
version 5.4, the module Binomial Superiority Trials: two-
sample test – difference of proportions, with the following
sample size parameters: control group proportion re-
sponse = 0.2, difference in proportion = 0.2, significance
level = 0.05 (two-sided), power = 90%, assigned fraction =
0.5 (randomization ratio = 1:1), unpooled standard devi-
ation and continuity correction for the standardized test
statistics; one unequally spaced interim look at 66% (2/3)
of the sample for sample size re-estimation, and the Lan–
DeMets with O’Brien–Fleming boundary to reject the null
hypothesis. These resulted in a total required sample size
of 212 randomized subjects (106 subjects per treatment
group). To reduce the possibility that one site with atypical
results will overly influence combined results, no site can
randomize more than 25 of 212 subjects without prior ap-
proval. If the sample size is extended, no site can
randomize more than 10% of the patients. Assuming 30%
pre-randomization attrition, up to 300 subjects may be
enrolled.
A single interim analysis is planned after 140 random-
ized subjects reach the end of Period I. This analysis will
provide data to support a decision to re-estimate the
sample size if necessary in order to achieve conditional
statistical power of at least 90%. For planning and
Table 1 PROMISE study – summary of data collection
Study procedure Enrollment Randomization Screening
test
Implant 1
montha
3
monthsb
6
monthsb
9
monthsb
12
monthsb
18
monthsb
24
monthsb
Unscheduled Early
discontinuec
Time window (days) −90 to 0 0 0 to 57 3 to 60 10 to 67 68 to 137 138 to 228 229 to 319 320 to 455 456 to 637 638 to 789 NA NA
Informed consent X
Demographics (age, gender) X
Medical history X
Inclusion/exclusion criteria X X
Pain location X X
Pain diary (complete prior
to visit)
X X X X X X X X X
OMM treatment plan X X X X X X X X
Questionnaires (ODI, SF-36, EQ-
5Dd, Pittsburgh Sleep Quality
Index, employment status, pain
and/or paresthesia map)
X X X X X X X X
Randomization assignment X
Neuropathic pain (DN4) X
PGIC, Patient satisfaction with
therapy
X X X X X X X
Nondrug pain treatment and
other healthcare use assessment
X X X X X X X X X X X
Payer information (US only) X X X
Medication assessment X X X X X X X X X X X
Event assessmentd X X X X X X X X X X X X
Screening test assessment X
Implant information X X
Request for change in
randomized therapy
X X X X X Xe
SCS therapy thresholds X
Device interrogation (initial and
final)
Xf X X X X X X X X X
DN4, Douleur neuropathique en 4 questions; ODI, Oswestry Disability Index; OMM, optimal medical management; PGIC, Patient Global Impression of Change; SF-36, Short-Form 36; SCS, spinal cord stimulation.
aFor subjects randomized to SCS, the 1-month visit should occur a minimum of 7 days after implant (or screening test if the test was unsuccessful).
bVisits should occur within the window but at least 2 weeks after the previous visit.
cEarly discontinuation, collect data if possible.
dWhen possible, collect additional EuroQoL (EQ-5D) at time of event if device-related event requiring surgical intervention or hospitalization occurred.
eOnly after 6 months.
fNo initial interrogation at implant, final only.
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tients is imposed for the final analysis.
Enrolment, randomization, and follow-up will con-
tinue during the interim analysis. The interim analysis
will be conducted by an independent statistician, and
one of the following possible outcomes will be commu-
nicated to the trial sponsor: continue the study with a
total of 212 subjects (implies that ≥90% conditional
power will be achieved with n = 212); or increase the
sample size to a specified size in order to achieve ≥90%
conditional power to achieve superiority based on the
observed interim results.
If the sample size must be increased, the sponsor will
determine whether or not to continue the study. It is
not anticipated that the sample size will be reduced
below 212.
Procedures to minimize bias
To minimize selection bias, randomization numbers will
be assigned in strict sequence; that is, when a subject is
confirmed as eligible for randomization, the next un-
assigned randomization number in sequence will be
given. Permuted blocks will be used to generate the
randomization assignments, in order to keep the balance
of patients receiving each treatment assignment and help
prevent the next treatment group from being discerned by
site personnel. Randomization allocation will be concealed
from the clinician and patient, using a centralized auto-
matic web-based data management system.
Regarding assessment bias, due to the nature of the
treatments, the study cannot be blinded (the form of
SCS used in this trial requires paresthesia); however, to
minimize potential assessment bias, questionnaires will
be completed by patients without study staff consult-
ation or visibility, using a secured electronic tablet.
To minimize attrition bias, if a subject misses a study
visit the site’s study staff will make at least three docu-
mented attempts to bring that subject in for a study
visit. The numbers and reasons for dropouts and losses
to follow-up will be reported for each arm of the study.
To quantify potential performance bias, the level of
OMM treatment and the addition/removal of SCS therapy
for all participants at each follow-up to 24 months will be
recorded. Additionally, we will compare changes in pain
medication use and other healthcare utilization from base-
line to the end of Period I for subjects in the SCS group
with those in the OMM group. Any imbalance in OMM
therapy between study arms will be considered in inter-
preting between-group outcome differences.
Data analysis
Statistical analysis
For primary and secondary objectives, the primary ana-
lysis method will follow the intention-to-treat principlesupported by completers’ and as-treated analyses. The
following definitions will be applied: intention-to-treat
analysis, between-group comparison based on random
allocation of all subjects at the 6-month visit; com-
pleters’ analysis, between-group comparison based on
random allocation of subjects with complete data at the
6-month visit; and as-treated analysis, between-group
analysis based on the treatment subjects with complete
data at the 6-month visit received at the 6-month visit.
The primary objective will be compared by Z-test using
unpooled standard deviation with continuity correction,
and a logistic regression model will be used for explora-
tory analysis. Secondary objectives will be assessed using
linear regression models. To assess potential differences in
treatment effect across sites, a treatment-by-site inter-
action term will be added to models. If the treatment-
by-site interaction term approaches significance (defined
as <0.10, as recommended by Fleiss [27]), the term will re-
main in the final model along with the term for site. In
this case, the results for the objective will also be tabulated
by site. Factors that might explain differences among sites
will be explored.
There is no compelling evidence of patient-related (for
example, age, sex) factors that predict the outcome of
SCS; however, in order to identify baseline characte-
ristics that might have predictive effects on outcomes,
exploratory analysis with regression models may be con-
ducted including baseline covariates. For the analysis of
secondary objectives, baseline assessments for pain score
and the Oswestry Disability Index will be included in the
regression models as covariates.
Missing data are a potential source of bias. A rigorous
study design and execution will help prevent the inci-
dence of missing data from occurring. For the primary
objective, patients with missing data at the end of Period
I will be treated as nonresponders (failures). With this
approach, we assume that nonresponders in both treat-
ment groups have no change in their outcomes com-
pared with baseline. This method has been chosen over
more complex imputation methods, such as multiple
imputation, because it has been empirically demon-
strated in trials of chronic pain to produce conservative
treatment effects [28]. For the secondary study objec-
tives, no change from baseline will be assumed for pa-
tients with missing data. For completers’ and as-treated
supporting analyses, only completers will be included in
the analysis.
Period II is the long-term follow-up phase, which in-
cludes the possibility for patients to change from their ori-
ginal treatment assignment to the alternative treatment.
The objectives of Period II are to compare within-patient
changes (that is, baseline versus follow-up) in each group.
Because the study design allows patients to change
from the randomized treatment group to the alternative
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jectives in Period II will be based on the treatment patients
actually received and not on the randomization assign-
ment. Only completers will be included.
Unadjusted P values will be reported. To maintain an
overall type I error rate at 0.05, a fixed-sequence method
for the multiplicity adjustment of hierarchical endpoints
will be used to test the primary and secondary objec-
tives. No multiplicity adjustment will be performed for
evaluations of the additional study objectives. A vali-
dated statistical software package will be used for the
analyses of the study results (for example, SAS, SPLUS).
These analyses are detailed in a statistical analysis plan.
Economic evaluation
Economic analyses consider the costs and effectiveness
of treatments. Costs will be calculated by multiplying
units of healthcare use used by the cost of each unit. Ef-
fectiveness will be expressed as quality-adjusted life-
years, with these data derived from patients’ responses
to the EQ-5D-5 L.
A within-trial cost-consequence analysis will include a
disaggregated report of costs and quality-adjusted life-
years and of other health outcomes observed in the two
groups at 6, 12, and 24 months [29]. Cost utility analysis
modeling, extrapolated over a longer time horizon (that
is, 15 years), will estimate the incremental cost per
quality-adjusted life-year ratio for SCS and OMM. These
analyses will be detailed later in a health economic ana-
lysis plan.
Ethics and governance
Each investigation site’s Ethics Committee/Institutional
Review Board (EC/IRB) will be required to approve the
clinical investigational plan (CIP), the written patient in-
formation and consent form, any other written informa-
tion to be provided to the patients, and, if applicable,
product labeling and materials used to recruit patients.
EC/IRB approval of the study must be provided in the
form of a letter before commencement of the study at
the investigation site. Site EC/IRB approvals at the time
of submission (3 July 2013) of this protocol are listed in
Additional file 2.
Each principal investigator will ensure that no study-
related activities occur prior to EC/IRB approval and will
provide adequate oversight to ensure that the study is
conducted in accordance with the outlined standards.
Study conduct will be in accordance with the ethical
principles that have their origin in the latest version of
the World Medical Association Declaration of Helsinki –
Ethical Principles for Medical Research Involving Hu-
man Subjects (October 2008), Clinical Investigation of
Medical Devices for Human Subjects – Good Clinical
Practice (International Organization for Standardization14155:2011) [30] and the laws and regulations of the
countries in which the study is conducted (including
data protection laws) and the requirements of the study
CIP.
Prior to site initiation or subsequent involvement in
study activities, the sponsor will provide study training
relevant and pertinent to the personnel conducting study
activities, including investigator responsibilities and de-
vice training (for example, study recommendations for
implant procedures and programming, and the require-
ments of the CIP, informed consent process, and case re-
port forms). Study-specific training will be documented
prior to site initiation.
Monitoring visits will be conducted periodically ac-
cording to the requirements of the study monitoring
plan. The monitoring plan will also define source data to
be directly recorded on the electronic clinical report
form. This information will be provided to the site dur-
ing site initiation. After site initiation and training, mon-
itoring visits will be conducted periodically to assess site
study progress, the investigator’s adherence to the CIP,
regulatory compliance (including but not limited to EC/
IRB approval and review of the study), maintenance of
records and reports, and review of source documents
against patient electronic clinical report forms. Monitors
will facilitate site regulatory and study compliance by
identifying any findings of noncompliance and commu-
nicating those findings along with recommendations for
preventative/corrective actions to site personnel. Moni-
tors may work with study personnel to determine and
recommend appropriate corrective action(s) and to iden-
tify trends within the study or at a particular site.
Trial committees
The PROMISE Steering Committee consists of renowned
specialists with expertise in the area of pain management
and FBSS surgical procedures (PR, MJD, RBN, KK), statis-
tics (RST), and health economics (LA). The committee
will meet periodically to advise on trial design and to
monitor enrolment, clinical site progress, and CIP compli-
ance. The Steering Committee also meets with representa-
tives of the sponsor (CG, CVdA) and is supported by a
Medtronic statistician (YT) and by a consultant (JS). A
data-monitoring committee will not be established for the
study because no interventions intended to prolong life or
reduce risk of a major adverse health outcome (for ex-
ample, a cardiovascular event) are evaluated for which fa-
vorable or unfavorable study results might suggest study
termination, and nor are there safety concerns suggesting
the need for a data-monitoring committee.
A publication committee will develop a publication
strategy and oversee the development and review of
publications related to the study. The publication com-
mittee will include members of the steering committee
Rigoard et al. Trials 2013, 14:376 Page 9 of 10
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(CG, YT). The publication committee will be responsible
for overseeing and ensuring that the publication strategy
is executed according to the established plan.
An independent clinical events committee consisting
of a minimum of three independent physicians will re-
view adverse events to determine any relationship to the
SCS therapy.
Discussion
The two published RCTs on the effectiveness of SCS
have explicitly included only subjects with leg pain pre-
dominant or equaling low back pain [6,10]. Few of the
numerous case series of SCS for FBSS have considered a
predominant low back pain population [31].
The PROMISE trial seeks to provide clinical evidence
on pain scores, function, health-related quality of life,
and cost-effectiveness for FBSS patients with predomin-
ant low back pain being treated with SCS using the Spe-
cify® 5-6-5 multi-column lead.
Trial status
The PROMISE trial began patient recruitment in Janu-
ary 2013. Recruitment is expected to close in 2016. It is
anticipated that primary endpoint findings will be avail-
able in 2017.
Additional files
Additional file 1: Is the Specify® 5-6-5 surgical lead technical
description.
Additional file 2: Is a table presenting the Site Ethics/IRB approvals
(as of 3 July 2013).
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